HOUSTON and BEIJING, April 27, 2021 /PRNewswire/ — NUPROBE GLOBAL, a molecular diagnostics firm based mostly in Shanghai, China and Houston, Texas, has reached a strategic collaboration settlement with AcornMed Biotechnology Co., Ltd. (AcornMed). The 2 corporations have agreed to work collectively to develop merchandise for minimal residual illness (MRD) detection in genitourinary tract most cancers and hematological most cancers utilizing NuProbe’s blocker displacement amplification (BDA) know-how.
NuProbe’s patented BDA know-how is a singular and novel PCR-based enrichment technique. By modern thermodynamic design within the PCR amplification cycles, BDA know-how successfully reduces the wild-type amplification effectivity and enlarges low frequency mutation indicators. Because of this, the BDA know-how permits for the selective amplification of low ample sequence variants (equivalent to SNVs and indels) in a background of wildtype DNA, thereby considerably bettering mutation detection sensitivity. BDA know-how is broadly appropriate with numerous molecular diagnostic platforms together with PCR, first-generation capillary sequencing, next-generation high-throughput sequencing, third-generation single-molecule sequencing, and mass spectrometry of nucleic acids. For extra info on BDA, go to NuProbe’s web site.
“BDA know-how enriches low-abundance variants by preferentially amplifying variants towards wild-type DNA, which remarkably reduces information on wild-type sequences when utilizing strategies equivalent to NGS. Due to this fact, the variety of reads wanted is decreased by over 50-fold, resulting in a major price discount for medical genetic testing whereas bettering detection sensitivity,” mentioned Dr. Junfeng Luo, Vice President of R&D at NuProbe. “BDA know-how has extensive functions together with liquid biopsy testing, rejection monitoring after organ transplantation, and microbial an infection. It has been validated in medical laboratories in China and the USA.”
Dr. Feng Lou, Chief Expertise Officer and co-founder of AcornMed, commented, “AcornMed is likely one of the few corporations in China that ranks prime in each the stable tumor and blood most cancers industries. We’ve got launched greater than 30 merchandise for hereditary most cancers testing, companion diagnostics for focused therapy and immunotherapy, and tumor diagnostic stratification. Moreover, we’re actively partaking within the fields of early prognosis and screening, prognostic analysis, and real-time monitoring for a number of most cancers varieties. NuProbe’s know-how can enhance the NGS mutation detection sensitivity by 100-fold, which may be very appropriate for MRD detection merchandise.”
The 2 corporations plan to collaborate on growing testing strategies for mutation detection utilizing repeatedly collected urine or plasma samples to observe therapy efficacy and information additional therapy methods.
“AcornMed is the one firm with each a proprietary genomic database in genitourinary tract tumors and probably the most complete genomic database of blood malignancies in China,” Yingshuang Chai, Chief Govt Officer of NuProbe, added. “Combining their sources with our extremely delicate BDA know-how, we anticipate to carry revolutionary merchandise to the oncology area.”
“We look ahead to collaborating with NuProbe to discover extra translational functions. This collaboration will help us to use our sequencing know-how to broader areas of medical oncology,” acknowledged Dr. Shanbo Cao, Chief Govt Officer of AcornMed.
About NuProbe World
NuProbe is a cutting-edge genomics and molecular diagnostics firm with revolutionary molecular diagnostic applied sciences to enhance the sensitivity of sequencing mutations and duplicate quantity variations by over 10-fold. NuProbe has websites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s imaginative and prescient is to supply inexpensive, well timed, and correct illness state info to allow precision medication and enhance affected person outcomes.
Official web site: http://www.nuprobe.com.cn and http://www.nuprobe.com
AcornMed, also called AcornMed Biotechnology Co., Ltd., is a high-tech enterprise guided by ideas of full-process system innovation. Headquartered in Beijing Financial-Technological Improvement Space, AcornMed has established two testing and R&D facilities in Beijing and Tianjin, with a complete space of 5,000 sq. meters. With an independently developed genomic massive information evaluation platform, the corporate offers precision medical options for medical oncology with genomics as its core. As one of many few NGS medical service corporations main each the stable tumor and blood most cancers industries, AcornMed has established distinctive model benefits in lung most cancers, gastrointestinal most cancers, genitourinary tract most cancers and hematologic malignancies. They’ve been endorsed by many medical oncologists and laboratory professionals and have served greater than 500 hospitals.
Official web site: http://www.acornmed.com/
CONTACT: Rachel Reed, [email protected]
— to www.prnewswire.com